Baumann, Tiffany

Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial

Mummery, C. J., Börjesson-Hanson, A., Blackburn, D. J., Vijverberg, E. G. B., De Deyn, P. P., Ducharme, S., Jonsson, M., Schneider, A., Rinne, J. O., Ludolph, A. C., et al. (2023) · Nature Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 347

A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer’s disease

Rafii, M. S., Baumann, T. L., Bakay, R. A. E., Ostrove, J. M., Siffert, J., Fleisher, A. S., Herzog, C. D., Barba, D., Pay, M., Salmon, D. P., et al. (2014) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsVirus-based gene therapy research

Cited by 223

Effects of IONIS-HTTRx in Patients with Early Huntington’s Disease, Results of the First HTT-Lowering Drug Trial (CT.002)

Tabrizi, S., Leavitt, B., Kordasiewicz, H., Czech, C., Swayze, E., Norris, D. A., Baumann, T., Gerlach, I., Schobel, S., Smith, A., et al. (2018) · Neurology

Genetic Neurodegenerative DiseasesAmyotrophic Lateral Sclerosis Research

Cited by 26

Results of the first-in-human, randomized, double-blind, placebo-controlled phase 1b study of lumbar intrathecal bolus administrations of antisense oligonucleotide (ISIS 814907; BIIB080) targeting tau mRNA in patients with mild Alzheimer's disease

Mummery, C. J., Junge, C., Kordasiewicz, H. B., Mignon, L., Moore, K. M., Yun, C., Baumann, T. L., Li, D., Norris, D. A., Crean, R., et al. (2021) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 16